International Journal of Molecular Sciences (Mar 2014)

Correction: Kikuchi, K., et al., Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke. Int. J. Mol. Sci. 2013, 14, 18899–18924.

  • Kiyoshi Kikuchi,
  • Salunya Tancharoen,
  • Takashi Ito,
  • Yoko Morimoto-Yamashita,
  • Naoki Miura,
  • Ko-ichi Kawahara,
  • Ikuro Maruyama,
  • Yoshinaka Murai,
  • Eiichiro Tanaka

DOI
https://doi.org/10.3390/ijms15045410
Journal volume & issue
Vol. 15, no. 4
pp. 5410 – 5411

Abstract

Read online

The original version of the paper [1] reports that “This ACTIVE I study was supported by Pfizer” (Page 18905). However, the sponsors of the ACTIVE I study were actually Bristol-Myers Squibb and Sanofi-Aventis rather than Pfizer.

Keywords